Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 10/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090912 | 0.92 | CTSK (0.48) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4993247 | 0.91 | NPSR1 (0.40) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4993253 | 0.91 | NPSR1 (0.40) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4428267 | 0.89 | NPSR1 (0.38) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14090986 | 0.89 | NPSR1 (0.44) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14090990 | 0.89 | NPSR1 (0.40) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14090988 | 0.88 | ALOX5 (0.38) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14090888 | 0.88 | CNR2 (0.39) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14090999 | 0.87 | NPSR1 (0.39) | NPSR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27793039 | 0.86 | CTSK (0.38) | NPSR1MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611008-A | C3A receptor modulators and methods of use thereof | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | NPSR1 474/4885MEN1 2114/4885KMT2A 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.